Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for SMSMY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SMSMY and 80,000+ other tickers.
See exactly how SMSMY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SMSMY and 80,000+ other tickers.
Sims Ltd. engages in the recycling of metal and electronics. It operates through the following segments: North America Metals (NAM), Australia, New Zealand Metals (ANZ), UK Metal (UK), Global Trading, Investment in SA Recycling (SAR), Sims Lifecycle Services (SLS), and Unallocated. The NAM segment consists of subsidiaries and joint ventures in the U.S. and Canada, which perform ferrous and non-ferrous secondary recycling functions. The ANZ segment includes subsidiaries and joint arrangements in Australia, New Zealand, and Papua New Guinea, which perform ferrous and non-ferrous secondary…
NEEDHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Mark Sims as the Company's Chief Commercial Officer, effective July 6, 2026. Mr. Sims will lead Candel's commercial strategy and launch readiness for aglatimagene besadenovec (aglatimagene or CAN-2409) in intermediate- to high-risk localized prostate cancer.
Sims Metal Management (SMSMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here is how GDS Holdings (GDS) and Sims Metal Management Ltd. (SMSMY) have performed compared to their sector so far this year.
Sims Limited (SMSMY) Analyst/Investor Day Transcript
Sims Limited (SMSMY) Analyst/Investor Day Transcript